Mark Jerome Pykett
Independent Non-Executive Vice ChairmanDr. Mark Jerome Pykett, V.M.D., Ph.D., MBA, served as Chief Executive Officer at Myrtelle Inc. He serves as Non-Executive Director at Pharming Group N.V. since December 11, 2020 and serves as its Vice Chairman of the Board. He joined PTC Therapeutics, Inc. in January 7, 2019 and served as Chief Scientific Officer until May 2021 and served as a Chief Innovation Officer since August 2018 until January 7, 2019. Dr. Pykett was the Chief Executive Officer and President of Agilis Biotherapeutics, LLC since September 10, 2014. Dr. Pykett served as Business Development Advisor at Hemogenyx Pharmaceuticals Plc until 2020. He served as the Chief Executive Officer of Navidea Biopharmaceuticals, Inc (formerly, Neoprobe Corp). from April 15, 2011 to May 15, 2014 and served as its President from April 15, 2011 to April 2013. Dr. Pykett has years of scientific, clinical, operational and commercial experience and proven leadership in the biotechnology, pharmaceutical and healthcare industries. Dr. Pykett served as the Chief Development Officer and Executive Vice President of Navidea Biopharmaceuticals, Inc. since November 2010. Dr. Pykett held senior leadership positions at several biotechnology and diagnostics companies where he was charged with product and corporate development efforts. As Chief Executive Officer and Founder of Talaris Advisors, a strategic drug development company serving the biotech industry, he led portfolio management efforts focusing on milestone acceleration and capital efficiency for clients in a range of therapeutic areas, including oncology, dermatology and transplantation. Dr. Pykett served as the President and Chief Financial Officer of Alseres Pharmaceuticals, Inc. (also known Boston Life Sciences Inc.) from February 3, 2005 to January 4, 2010. Dr. Pykett served as the Chief Operating Officer of Alseres Pharmaceuticals, Inc. from October 29, 2004 to January 4, 2010. Prior to Alseres, Dr. Pykett co-founded and led three development-stage biotechnology companies - Cygenics, Oramax and Cytomatrix -- where he was responsible for overall management, capital formation and development efforts. Dr. Pykett served as President and served as Executive Director of Cordlife Limited (also known as CyGenics Ltd.) from February 24, 2004 to February 1, 2005. Dr. Pykett was responsible for guiding the daily operations and strategic development of Cordlife Limited in the USA. He served as Executive Vice President of Alseres Pharmaceuticals, Inc. from October 29, 2004 to February 4, 2005. His management role includes coordination of Cordlife Limited, technical and Commercialisation programs, grants and contracts unit. He also oversees the quality, regulatory and clinical trials units, intellectual property function and financing and audit teams. He has experience in the development of early stage biomedical technologies. Prior to joining Alseres Pharmaceuticals, Inc., Dr. Pykett served as President, Chief Operating Officer and Chief Executive Officer of Cytomatrix LLC. He served as the President at Cordlife Pte Ltd., from 2003 to 2004. He has been a Director of Exubrion Therapeutics, Inc. Dr. Pykett served as a Director at Navidea Biopharmaceuticals, Inc (Neoprobe Corp.) from August 2011 until July 17, 2014. He served as a Director of Mast Therapeutics, Inc. (Adventrx Pharmaceuticals Inc). (formerly, Biokeys Pharmaceuticals Inc.) from January 2004 to June 15, 2011. He served as Director of Cytomatrix LLC. He served as a Non-Executive Director of Cordlife Limited from February 1, 2005 to November 23, 2005. He served as Chairman and Member of Scientific Advisory Board Cordlife Limited. In his research in academia, Dr. Pykett focused on understanding the molecular basis of cancer. Dr. Pykett is also a director of the not-for-profit organization HealthBuilders, developing health infrastructure in central Africa. Dr. Pykett also held an adjunct faculty position at the Harvard School of Public Health from 1997 to 2003. He has also served as an adjunct lecturer in cancer biology at Harvard University's School of Public Health and served on Northeastern University's Center for Enterprise Growth Corporate Advisory Board. Dr. Pykett holds a BA in Biology from Amherst College. He holds a PhD in Molecular Biology from the University of Pennsylvania, a VMD from the University of Pennsylvania School of Veterinary Medicine. He holds an MBA from Northeastern University. He completed post-doctoral fellowships at the University of Pennsylvania and Harvard University.
Positions
- Company NamePharming Group N.V.Stock CodePHARPositionIndependent Non-Executive Vice ChairmanColleagues
- KLKenneth LynardCFO & Co-Chief Executive Officer
- RPRichard PetersNon-Executive Chairman of Board
- LMLeverne MarshCo-CEO & Chief Commercial Officer
- MSMireille SandersChief Operations Officer
- MKMichael K. LevitanVP of Investor Relations & Corporate Communications
- RVRuud Van OutersterpChief Legal & Compliance Officer and Company Secretary
- JTJabine T. M. van der MeijsIndependent Non-Executive Director
- LKLeonard KruimerIndependent Non-Executive Director
- ESElaine SullivanNon Executive Director
